GSBS Alumnus Kopchick Named National Academy of Inventors FellowDecember 21, 2012
The University of Texas Graduate School of Biomedical Sciences at Houston alumnus John Kopchick, Ph.D., has been named a 2012 National Academy of Inventors Charter Fellow and will be inducted into the Academy at its annual conference to be held on Feb. 22, 2013, in Tampa, Fla.
Kopchick is a professor of Molecular Biology and the Goll-Ohio Eminent Scholar at the Department of Biomedical Sciences at Ohio University’s Heritage College of Osteopathic Medicine. He holds 16 U.S. patents, one foreign patent and has seven patents pending. His accolades include the discovery of a growth hormone antagonist that led to the development of the Pfizer drug SOMAVERT® (pegvisomant for injection) which is used in the treatment for acromegaly, a form of gigantism marked by excessive levels of growth hormone that result in enlargement of the hands and feet, facial disfiguration, and multiple organ disorders, which can lead to premature death.
Kopchick is one of 98 innovators named by the Academy as a 2012 NAI Charter Fellow, representing 54 research universities and non-profit research institutes.
Kopchick graduated from GSBS in 1980 and was honored by the School as a distinguished alumnus in 2006. His advisor was Ralph Arlinghaus, Ph.D.